Fig. 9.

PET images of heterogeneous ⁸⁹Zr-bevacizumab accumulation in tumor lesions of metastatic renal cell carcinoma patients. a Serial ⁸⁹Zr-bevacizumab PET scans of patient with RCC metastases in the pancreas, liver, and thyroid, with associated jugular and portal vein thrombosis at baseline (left) and 2 (middle) and 6 weeks (right) after the start of bevacizumab/IFNα. b Serial ⁸⁹Zr-bevacizumab PET scans of patient with RCC metastases in the lungs, mediastinal lymph nodes, bone, and brain at baseline (left) and 2 (middle) and 6 weeks (right) after the start of sunitinib—that is, after 2 sunitinib-free weeks. Reprinted with permission from ref. 54. Copyright 2015 Society of Nuclear Medicine